EN 
FR 
Data-Driven Project-Based Analytical Solutions
Our customized, project-based analytical solutions are designed to meet your specific needs and challenges with efficiency, quality, timeliness and expertise to ensure successful outcomes at every stage of the drug development process.
Biometrics at Project Scale: Biostatistics, Programming, Data Management and Medical Writing
Cytel has a data-driven project-based solution to help. Our global team of experts can manage every biometric aspect of your trial, from design to report production, including biostatistics, statistical programming, data management and medical writing. With tailored approaches and a focus on data integrity, we ensure robust results while navigating complexities with precision.
Partner with us to unlock the full potential of your data and experience a seamless journey, without compromising scientific or regulatory rigor. With over thirty-five years of experience, we can enable your team to navigate uncertainty, prove value, and optimize your clinical trials with confidence.
Our Solutions
End-to-End Biometrics Solutions
Harness the power of data management, biostatistics, statistical programming, and medical writing to optimize your trial design, data analysis, and reporting. Our solutions ensure robust results and regulatory compliance throughout your clinical development journey.
Data Management
Our experts seamlessly orchestrate the collection, integration, cleaning, and coding of trial data from multiple sources (e.g., EDC, eSource, LAB, PK, eCOA, imaging) helping you to ensure accuracy, completeness, and regulatory compliance.
Data Monitoring Committees
Take advantage of our vigilant oversight of trial data to identify trends, anomalies, and potential issues, and ensure integrity throughout. Experienced data monitoring committees, with our Axio unit, ensure your regulatory compliance, guard patient safety, and foster trust in clinical trial outcomes.
Data Submission Support
We facilitate seamless submission of your trial data, ensuring compliance with regulatory requirements and enabling efficient integration for analysis and reporting.
100%
Acceptance of data sets by the FDA
>6,000
Phase I-III trials in the last 10 years
>35
Years of leadership in advanced analytics
69
Average Net Promoter Score, reflecting outstanding client satisfaction
Related Insights
Evaluating Safety and Efficacy in Phase III Alzheimer’s Disease Trial: Endpoints and Statistical Analysis Methods
Statistical Insight for Strategic Impact: How Statisticians Help Medical Affairs Make the Most of Their Data
Analyzing Endpoints in Multiple Sclerosis Clinical Trials: Statistical Considerations
Claim your free 30-minute strategy session
Book a free, no-obligation strategy session with a Cytel expert to get advice on how to improve your therapy’s probability of success and plot a clearer route to market.
